Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to “Strong Sell”

by · The Markets Daily

Wall Street Zen lowered shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a sell rating to a strong sell rating in a research report released on Sunday,Wall Street Zen reports.

Other equities analysts have also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $65.00 price objective on shares of Beam Therapeutics in a research report on Wednesday, September 9th. Bank of America reaffirmed a “buy” rating and set a $47.00 target price on shares of Beam Therapeutics in a research note on Wednesday, July 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Beam Therapeutics in a report on Tuesday, August 25th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $49.00.

Get Our Latest Analysis on Beam Therapeutics

Beam Therapeutics Stock Performance

Beam Therapeutics stock opened at $23.99 on Friday. The company has a quick ratio of 14.57, a current ratio of 14.57 and a debt-to-equity ratio of 0.09. The stock has a market cap of $2.48 billion, a PE ratio of -27.90 and a beta of 2.22. Beam Therapeutics has a 12-month low of $20.23 and a 12-month high of $38.26. The business’s 50-day moving average price is $28.50 and its two-hundred day moving average price is $28.89.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.07). Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%.The company had revenue of $0.49 million during the quarter, compared to the consensus estimate of $16.37 million. During the same period last year, the company posted ($1.00) EPS. The firm’s revenue was down 94.2% compared to the same quarter last year. As a group, analysts expect that Beam Therapeutics will post -4.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Fmr Llc sold 251,488 shares of Beam Therapeutics stock in a transaction on Friday, June 26th. The shares were sold at an average price of $35.26, for a total transaction of $8,867,466.88. Following the transaction, the insider owned 854,583 shares in the company, valued at approximately $30,132,596.58. The trade was a 22.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Amy Simon sold 16,667 shares of the business’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $25.74, for a total transaction of $429,008.58. Following the completion of the sale, the insider directly owned 85,696 shares in the company, valued at approximately $2,205,815.04. This represents a 16.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 301,527 shares of company stock worth $10,468,500 over the last three months. Insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BEAM. BlackRock Inc. acquired a new stake in shares of Beam Therapeutics in the second quarter valued at about $308,796,000. ARCH Venture Management LLC acquired a new position in shares of Beam Therapeutics in the second quarter worth approximately $155,771,929. California State Teachers Retirement System boosted its holdings in Beam Therapeutics by 3,228.9% in the second quarter. California State Teachers Retirement System now owns 3,586,612 shares of the company’s stock valued at $123,093,000 after acquiring an additional 3,478,871 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in Beam Therapeutics during the 1st quarter valued at approximately $34,467,000. Finally, ARK Investment Management LLC raised its holdings in Beam Therapeutics by 12.9% during the 4th quarter. ARK Investment Management LLC now owns 12,467,189 shares of the company’s stock worth $345,590,000 after purchasing an additional 1,428,355 shares during the last quarter. 99.68% of the stock is owned by institutional investors and hedge funds.

Beam Therapeutics News Roundup

Here are the key news stories impacting Beam Therapeutics this week:

  • Positive Sentiment: Analysts maintain bullish views. Wedbush reaffirmed its Buy/Outperform rating, while Canaccord Genuity and JonesTrading also maintained Buy ratings. Separately, the brokerage consensus remains “Moderate Buy,” supporting investor confidence in Beam’s pipeline and long-term prospects. Wedbush Reaffirms Their Buy Rating Wedbush Reiterates Outperform Rating Consensus Moderate Buy Rating
  • Positive Sentiment: BEAM-302 data show sustained biomarker improvement. Updated Phase 1/2 results in alpha-1 antitrypsin deficiency indicated that the investigational treatment restored AAT levels, with biomarker follow-up extending to 18 months. The results strengthen the case for continued development, although the study remains early stage and clinical benefit has not yet been conclusively established. BEAM-302 Clinical Data Analysis
  • Neutral Sentiment: Options activity increased. Unusually large options trading was reported, which may signal heightened speculation or hedging but does not establish a clear directional outlook for BEAM. Unusually Large Options Trading
  • Neutral Sentiment: Reports of a sharp increase in short interest showed zero shares both before and after the period, suggesting a data-quality issue rather than a meaningful change in bearish positioning.
  • Negative Sentiment: Pomerantz LLP is investigating potential investor claims. The law firm’s announcement may add legal and headline risk, although it does not allege that Beam has been found liable. Pomerantz Investor Investigation

About Beam Therapeutics

(Get Free Report)

Beam Therapeutics Inc is a biotechnology company focused on developing genetic medicines using its proprietary base-editing technology. Unlike conventional gene-editing approaches that can make double-strand breaks in DNA, base editing is designed to make targeted changes to individual DNA letters, with the goal of treating diseases at their genetic source.

The company is developing both ex vivo and in vivo therapies. Its pipeline has included programs for sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, glycogen storage disease type Ia and certain cancers.

Read More